Trial To Assess Efficacy Of A Chimeric Skin In Patients With Epidermolysys Bullosa

NCT ID: NCT00987142

Last Updated: 2019-08-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-12-31

Study Completion Date

2010-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A phase II, comparative, open label, prospective, multicentre clinical trial where each patient will undergo two procedures; implant of a patch of cultured chimeric skin (experimental therapy) in a half of the skin lesion and an occlusive non-adherent dressing (control) in the other half for 12 months of follow-up in two Spanish centres.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Reconstruction of interdigital commisures in patients with severe skin syndactyly using laminar grafts that will be uniformly and systematically taken with an electrical or compressed air dermatome on an aseptic area and with the same extent and depth in microns in all patients.

Immediately after the surgical procedure, a patch of cultured chimeric skin (experimental therapy) will be implanted in a half of the skin defect of the patient, and an occlusive non - adherent dressing (control) will be implanted in the other half.

Patients will initially be followed up every two days until epithelisation occurs (approximately 21 days after surgery) and at 3,8,and 12 months of follow-up.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

EPIDERMOLYSIS BULLOSA

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CX501

Cultured chimeric skin

Group Type EXPERIMENTAL

CX501

Intervention Type DRUG

Cultured chimeric skin

Non adherent dressing

Occlusive non adherent dressing

Group Type ACTIVE_COMPARATOR

Occlusive non adherent dressing

Intervention Type DEVICE

Application of an occlusive non adherent dressing in the skin donor site

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CX501

Cultured chimeric skin

Intervention Type DRUG

Occlusive non adherent dressing

Application of an occlusive non adherent dressing in the skin donor site

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients of both sexes over 28 days of age.
* Patients with recessive dystrophic epidermolysis bullosa diagnosed by clinical and historical criteria with severe skin syndactyly in whom reconstructive surgery is indicated.
* Patients whose legal guardians have given written informed consent for participation in the study before any study procedure is performed.
* Patients aged ≥ 12 years who have given written informed consent for participation in the study before any study procedure is performed.

Exclusion Criteria

* Women of childbearing age not using effective contraceptive methods (oral contraception)
* Pregnant or nursing women
* Documented or suspected hypersensitivity to any of the therapeutic agents included in the study, including anaesthetic drugs.
* Patients with a history of malignant tumor in the past 5 years
* Patients with a diagnosis of active tuberculosis at the time of recruitment
* Patients with prior positive markers for any of the following pathogens: hepatitis b and c, hiv-1 and hiv-2
* Patients with a history of clinically relevant hepatic, gastrointestinal, haematological, pulmonary, or neurological disease no directly related to epidermolysis bullosa.
* Any other medical condition which, in the investigator´s judgment, might interfere with optimal participation in the study or involve a significant risk for the patient.
* Alcoholism, drug addiction, psychiatric disorders, or other factors present in legal guardians which,in the investigator´s judgment may complicate patient participation in the study.
Minimum Eligible Age

28 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tigenix S.A.U.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Juan Carlos López, MD

Role: PRINCIPAL_INVESTIGATOR

Hospital La Paz

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Fundación Mir-Mir

Barcelona, , Spain

Site Status

Hospital La Paz

Madrid, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CX501/TCEB

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Epidermal Grafting in Wound Healing
NCT02535481 COMPLETED NA